Letko Brosseau & Associates Inc. Sells 551,496 Shares of Moderna, Inc. $MRNA

Key Points

• Letko Brosseau & Associates cut its Moderna stake by 76.1%, selling 551,496 shares in the third quarter and retaining 173,334 shares valued at about $33.4 million.
• Moderna reported quarterly EPS of $0.38, beating the consensus estimate of a $1.10 loss, while revenue of $1.31 billion exceeded estimates and rose 29.2% year over year.
• Moderna raised its 2026 revenue-growth outlook to 15%–25%, but its expected $4 billion in 2027 cash costs and concerns that sales may still fall short of analyst expectations weighed on sentiment.

Letko Brosseau & Associates Inc. cut its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 76.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 173,334 shares of the company's stock after selling 551,496 shares during the quarter. Letko Brosseau & Associates Inc.'s holdings in Moderna were worth $33,379,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in Moderna by 18.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 531,893 shares of the company's stock valued at $102,551,000 after purchasing an additional 84,445 shares during the last quarter. Werba Rubin Papier Wealth Management bought a new stake in Moderna in the third quarter worth about $269,000. CENTRAL TRUST Co lifted its stake in Moderna by 36.5% in the third quarter. CENTRAL TRUST Co now owns 172 shares of the company's stock worth $33,000 after purchasing an additional 46 shares during the last quarter. Fifth Third Bancorp lifted its stake in Moderna by 4.2% in the third quarter. Fifth Third Bancorp now owns 59,996 shares of the company's stock worth $11,554,000 after purchasing an additional 2,415 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its position in shares of Moderna by 16.6% during the third quarter. Maryland State Retirement & Pension System now owns 21,917 shares of the company's stock valued at $4,221,000 after buying an additional 3,126 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the firm's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 197,251 shares of company stock worth $33,875,904. Company insiders own 10.80% of the company's stock.

Moderna Trading Down 7.0%

Shares of MRNA opened at $231.35 on Friday. The firm has a market capitalization of $93.61 billion, a price-to-earnings ratio of -32.58 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $280.80. The company has a 50-day moving average of $200.18 and a 200 day moving average of $95.52.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping analysts' consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The company's revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.51) EPS. On average, research analysts expect that Moderna, Inc. will post -5.34 EPS for the current year.

Moderna News Summary

These are some of the MRNA news items that stood out recently:

• Positive Sentiment: Moderna raised its 2026 revenue-growth outlook to 15%–25%, up from its prior forecast of growth of up to 10%. Stronger overseas COVID-19 sales and the improved outlook provide near-term support. Article: Moderna Raises 2026 Revenue Growth Forecast
• Negative Sentiment: Investors focused on the cost of that strategy: Moderna expects about $4 billion in cash costs in 2027. The planned investment raises the stakes for its cancer programs and could prolong the path to profitability. Article: Moderna Analyst Day Spending
• Negative Sentiment: Despite the raised forecast, coverage noted that Moderna’s 2026 revenue outlook may still be below analyst expectations, fueling concern about a potential sales shortfall. That outlook, combined with elevated investment needs, appears to have outweighed the positive updates. Article: Why Moderna Stock Dropped

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MRNA shares. UBS Group reaffirmed a "neutral" rating on shares of Moderna in a research note on Tuesday, September 22nd. Argus raised Moderna from a "hold" rating to a "buy" rating and set a $180.00 price target for the company in a research note on Friday, August 28th. Wolfe Research upgraded Moderna from an "underperform" rating to a "peer perform" rating in a report on Tuesday, August 25th. CLSA upgraded Moderna to an "outperform" rating in a report on Friday, August 28th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Moderna in a research report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $113.75.

Moderna Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.